Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07932808
PHASE2

Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma

Sponsor: Giselle Sholler

View on ClinicalTrials.gov

Summary

A prospective, multicenter, clinical trial in participants with high-risk neuroblastoma that have completed induction therapy, evaluating the feasibility, efficacy, and toxicity of using anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF) as consolidation followed by standard radiation, then standard anti-GD2 immunotherapy, and 2 years of DFMO maintenance.

Official title: A Beat Childhood Cancer Research Consortium Phase II Trial of Transplant-Free Chemo-immunotherapy Consolidation Regimen With Naxitamab for High-Risk Neuroblastoma

Key Details

Gender

All

Age Range

1 Year - 30 Years

Study Type

INTERVENTIONAL

Enrollment

101

Start Date

2026-11-26

Completion Date

2040-11-26

Last Updated

2026-11-16

Healthy Volunteers

No

Conditions

Interventions

DRUG

Naxitamab and GM-CSF in combination with irinotecan and temozolomide

anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF) as consolidation

DRUG

Dinutuximab. Immunotherapy

Dinutuximab + GM-CSF + Isotretinoin (or Dinutuximab-Beta) for 5 cycles plus Isotretinoin alone in Cycle 6

DRUG

DFMO

DFMO Monotherapy: DFMO for 730 days (2 years)

Locations (1)

Penn State Milton S. Hershey Medical Center and Children's Hospital

Hershey, Pennsylvania, United States